此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

2026年11月13日 更新者:Regeneron Pharmaceuticals

A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors

This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).

The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.

The study is looking at:

  • What side effects the study drug might cause
  • How well the study drug works
  • How much of the study drug is in the blood at different times
  • If the body reacts to the study drug, in a way that may cause the study drug to not work as well
  • What is the best dose of the study drug for treating previously treated, advanced solid tumors

研究概览

地位

招聘中

研究类型

介入性

注册 (估计的)

320

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • North Carolina
      • Huntersville、North Carolina、美国、28078
        • 招聘中
        • Carolina BioOncology Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  1. Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroesophageal junction cancer, uveal melanoma, papillary renal cell carcinoma, or clear cell renal cell carcinoma) that is at an advanced stage as described in the protocol
  2. Participants must not be candidates for curative surgery or radiation
  3. Participants are required to have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy as described in the protocol
  4. Willing to provide tumor tissue; archival or fresh tumor tissue will be accepted as described in the protocol
  5. At least 1 lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  7. Adequate organ and bone marrow function as described in the protocol

Key Exclusion Criteria:

  1. Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device as described in the protocol
  2. Has received radiation therapy within the 28 days prior to first administration of study intervention. Palliative stereotactic radiation therapy without a thoracic or abdominal field is allowed with a washout period of 14 days from first administration of study intervention.
  3. Has undergone major surgery within the 14 days prior to first administration of study intervention
  4. Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy as described in the protocol
  5. Has a history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, etc) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management or has imaging consistent with these diseases during the screening period. A history of radiation pneumonitis is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
  6. Has received prior treatment with an antibody-drug conjugate (ADC) that includes a topoisomerase payload
  7. Known active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated, and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.

Note: Other protocol defined inclusion/ exclusion criteria apply

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:第 1 部分:剂量递增

Administered per the protocol

实验性的:第 2 部分:剂量扩展

Administered per the protocol

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Occurrence of dose-limiting toxicities (DLTs)
大体时间:Up to 21 days

Part 1 (Dose Escalation)

Up to 21 days
Occurrence of Treatment Emergent Adverse Events (TEAEs)
大体时间:Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Occurrence of Serious Adverse Events (SAEs)
大体时间:Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Occurrence of adverse event of special interests (AESIs)
大体时间:Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
大体时间:Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years

次要结果测量

结果测量
措施说明
大体时间
Objective response (investigator assessed) per RECIST 1.1
大体时间:Up to approximately 5 years

Part 1 (Dose Escalation)

Up to approximately 5 years
Concentrations of ADC
大体时间:Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Concentrations of total antibody
大体时间:Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Concentrations of payload (ProDXd and DXd)
大体时间:Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980
大体时间:Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Magnitude of ADA against REGN13089-M404-M2980
大体时间:Up to approximately 5 years

Part 1 (Dose Escalation) and Part 2 (Dose Expansion)

Up to approximately 5 years
Duration of response per RECIST 1.1
大体时间:Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Time to response per RECIST 1.1
大体时间:Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Progression-free survival per RECIST 1.1
大体时间:Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Overall survival
大体时间:Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Occurrence of TEAEs considered clinically significant
大体时间:Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years
Laboratory abnormalities considered clinically significant
大体时间:Up to approximately 5 years

Part 2 (Dose Expansion)

Up to approximately 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月28日

初级完成 (估计的)

2031年3月10日

研究完成 (估计的)

2031年3月10日

研究注册日期

首次提交

2026年10月2日

首先提交符合 QC 标准的

2026年10月2日

首次发布 (实际的)

2026年10月7日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD 共享时间框架

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD 共享访问标准

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅